As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: May 14, 2012
by Raquel Maurier for Medical XPress:
A medical research team at the University of Alberta has made two related discoveries that could shed more light on Alzheimer’s disease.
Faculty of Medicine & Dentistry researcher Elena Posse de Chaves and her team recently published their findings in The Journal of Neuroscience.
It has been known for decades that cholesterol plays an important role in Alzheimer’s disease. Posse de Chaves’ team discovered that, in brain cells that accumulate toxic levels of the normally occurring beta amyloid protein, “there is a significant inhibition” in the process that creates brain cholesterol.
Brain cholesterol is vital for normal brain function because it helps protect neurons and helps brain cells fire properly. What the discovery means is that the relationship between this naturally occurring protein and cholesterol is not just one-way. These findings have been suggested by other research teams as well.
“Our work supports the idea that there is a two-way relationship,” said Posse de Chaves, a researcher in the Department of Pharmacology.
Her team’s work is also important in another area. Those who have Alzheimer’s disease have low levels of a protein known as seladin-1. Some researchers believe this could be an indicator for the disease. This protein is part of the process that leads to the creation of cholesterol. So if cholesterol production is inhibited in Alzheimer’s disease, as demonstrated by the U of A findings, this could explain why levels of the seladin-1 protein are so low.
“Our findings could explain why that one protein is decreased in the brains of patients with Alzheimer’s disease,” said Posse de Chaves. “This is one piece of the puzzle and every discovery helps.”
According to the Alzheimer Society of Canada, more than 500,000 people in Canada and more than 35 million worldwide have dementia, a group of brain disorders that includes Alzheimer’s disease.
The Canadian Institutes of Health Research and the Alzheimer Society of Canada funded the research.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.